| B18 | Incidence and risk factors of ischemic stroke and transient ischemic attack among Thai HIV-infected individuals: a longitudinal cohort study | E-poster | Neurologic disorders |
| B18 | Poor sleep quality in people with HIV linked to lower amyloid beta 42 levels in cerebrospinal fluid | E-poster | Neurologic disorders |
| B43 | Islatravir safety analysis through week 96 from a phase 2 trial in treatment naïve adults with HIV-1 infection | On-demand oral abstract session | New strategies (2DR, rapid start) |
| B43 | Five years durability of dolutegravir + lamivudine in patients with suppressed HIV-RNA | E-poster | New strategies (2DR, rapid start) |
| B43 | Immediate versus delayed antiretroviral treatment in hospitalized persons with AIDS-defining opportunistic disease: a randomized clinical trial | E-poster | New strategies (2DR, rapid start) |
| B43 | Largely increasing amounts of patients under dual ART due to new therapeutic regimens: dual therapy regimens 2016-2020 in the German North Rhine Cohort | E-poster | New strategies (2DR, rapid start) |
| B43 | Feasibility, efficacy, and safety of Dolutegravir/Lamivudine (DTG/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV (PLWH): 48-week results of the STAT study | E-poster | New strategies (2DR, rapid start) |
| B43 | 48 weeks efficacy and tolerability of dolutegravir (DTG) + lamivudine (3TC) in adult HIV naïve patients. A multicenter real life cohort | E-poster | New strategies (2DR, rapid start) |
| B43 | Immediate ART is feasible during the COVID-19 pandemic | E-poster | New strategies (2DR, rapid start) |
| A49 | Antibody responses of cows immunized with HIV V2-apex focusing immunogens | E-poster | Novel animal models to test interventions (vaccines, cure, antiretrovirals) |